| Field | Specification |
|---|---|
| Mfr No | |
| Clonality | |
| Host | |
| Immunogen | A synthetic peptide corresponding to a sequence in the middle region of human FGL1 was used as the immunogen for the FGL1 antibody. |
| Isotype | |
| Product Type | |
| Purity | |
| Reactivity | |
| Storage | |
| Target | |
| UniProt # |
Overview
FGL1 Antibody / Fibrinogen-like protein 1 is a anti-FGL1 Rabbit antibody Polyclonal (rabbit origin) supplied in Lyophilized format. Recommended for workflows such as Western blot (WB), Immunohistochemistry (IHC) with listed reactivity in Human, Mouse, Rat.
Key elements and design rationale
- Target: FGL1
- Antibody details: Rabbit, Polyclonal (rabbit origin), isotype Rabbit IgG
- Format: Lyophilized
- Applications (as listed): WB, IHC
Biological background
FGL1 is encoded by the FGL1 gene located on human chromosome 8p22. The protein is approximately 312 amino acids long and contains a fibrinogen-like domain that mediates binding to the lymphocyte-activation gene 3 (LAG-3) receptor. FGL1 is predominantly expressed in the liver but can also be produced by tumor cells and tissues under regenerative or inflammatory conditions. It is secreted into plasma, acting in both paracrine and systemic signaling.
The FGL1 antibody detects a 35 kilodalton protein by western blot and shows cytoplasmic and secretory vesicle localization under immunostaining. In normal physiology, FGL1 supports hepatocyte proliferation and tissue regeneration following liver injury by activating ERK and STAT3 pathways. In the immune system, FGL1 serves as a non-MHC ligand for LAG-3, suppressing effector T-cell activation and cytokine release, thereby promoting immune tolerance.
In cancer, FGL1 is frequently upregulated and mediates resistance to immunotherapies targeting the PD-1/PD-L1 axis. High expression correlates with poor prognosis in hepatocellular carcinoma, lung cancer, and melanoma. Neutralization of FGL1 enhances antitumor immunity, making it an emerging therapeutic target for combination checkpoint blockade. Beyond oncology, altered FGL1 levels are associated with metabolic disorders and liver fibrosis.
As a multifunctional factor bridging liver regeneration and immune suppression, FGL1 provides critical insights into tissue repair and immune escape.
Research relevance and current trends
- Connecting protein-level changes to phenotype using orthogonal readouts (genetic perturbation, transcriptomics, imaging).
- Considering isoforms and post-translational regulation when interpreting protein-level changes.
- Comparing results across species and model systems with matched controls.
Common research applications
- Western blotting: compare relative abundance and activation-state changes across conditions.
- Immunohistochemistry: map target signal in tissue context and compare regions/phenotypes.
Interpret changes in signal alongside appropriate controls and, when relevant, in parallel with total-protein or pathway readouts.
Notes for experimental interpretation
- Signal can reflect expression level, isoform composition, and post-translational state; interpret results in the context of your model system and stimuli.
- Species differences and sample matrices can influence epitope recognition; prioritize matched controls and orthogonal confirmation when feasible.
Antibody notes: Polyclonal antibodies recognize multiple epitopes, which can broaden the epitope footprint and may increase sensitivity in some contexts.
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
